 | Thomas E RollinsSepracor Inc., Marlborough, Massachusetts | Denver, Colo, Stockton and Encinitas, Calif, Wilmington, NC, and Marlborough, Mass |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Thomas E Rollins:Expert Impact
Concepts for whichThomas E Rollinshas direct influence:Racemic albuterol,Levalbuterol racemic albuterol,Patients levalbuterol,Racemic albuterol patients,Patients asthma,Bronchodilator agents,Levalbuterol placebo,250 levalbuterol.
Thomas E Rollins:KOL impact
Concepts related to the work of other authors for whichfor which Thomas E Rollins has influence:Racemic albuterol,Acute asthma,Rac lev,Bronchodilator agents,Beta agonists.
KOL Resume for Thomas E Rollins
| Year | |
|---|---|
| 2000 | Sepracor Inc., Marlborough, Massachusetts |
| 1998 | Denver, Colo, Stockton and Encinitas, Calif, Wilmington, NC, and Marlborough, Mass |
| Concept | World rank |
|---|---|
| 063 provided | #4 |
| 063 levalbuterol | #4 |
| racemic albuterol 250 | #4 |
| highdose levalbuterol | #4 |
| levalbuterol 063 | #4 |
| single nebulized doses | #4 |
| 250 levalbuterol | #4 |
| levalbuterol levalbuterol 125 | #4 |
| improvement racemic | #4 |
| duration fev1 improvement | #4 |
| single isomer version | #4 |
| 125 provided | #5 |
| albuterol 250 | #5 |
| marketed forms | #5 |
| 250 racemic | #6 |
| 063 racemic | #7 |
| combined racemic | #7 |
| electrocardiogram ecg readings | #7 |
| 125 racemic | #8 |
| racemic albuterol placebo | #8 |
| levalbuterol compared | #8 |
| levalbuterol patients | #9 |
| levalbuterol 125 | #10 |
| ralbuterol levalbuterol | #10 |
| racemic albuterol patients | #10 |
| albuterol 125 | #13 |
| received levalbuterol | #13 |
| doses levalbuterol | #15 |
| dose levalbuterol | #16 |
| albuterol single | #17 |
| received racemic | #19 |
| serial pulmonary function | #19 |
| levalbuterol placebo | #20 |
| patient subjective assessment | #20 |
| levalbuterol administered | #24 |
| levalbuterol versus | #24 |
| patients levalbuterol | #27 |
| levalbuterol racemic albuterol | #32 |
| versus racemic | #40 |
| duration fev1 | #43 |
| albuterol 25 | #54 |
| levalbuterol | #71 |
| 063 125 | #73 |
| racemic albuterol | #74 |
| compared racemic | #87 |
| Sign-in to see all concepts, it's free! | |
Prominent publications by Thomas E Rollins
Improved bronchodilation with levalbuterol compared with racemic albuterol in patients with asthma
[ PUBLICATION ]
BACKGROUND: Racemic albuterol is an equal mixture of (R)-albuterol (levalbuterol), which is responsible for the bronchodilator effect, and (S)-albuterol, which provides no benefit and may be detrimental.
OBJECTIVE: We sought to compare 2 doses of a single enantiomer, levalbuterol (0.63 mg and 1.25 mg), and equivalent amounts of levalbuterol administered as racemic albuterol with placebo in patients with moderate-to-severe asthma.
METHODS: This was a randomized, double-blind, ...
| Known for Racemic Albuterol | Placebo Patients | 4 Weeks | Asthma Bronchodilator | Primary Endpoint |
Dose-Response Evaluation of Levalbuterol Versus Racemic Albuterol in Patients with Asthma
[ PUBLICATION ]
Albuterol, in all marketed forms, is sold as a racemate, composed of a 50:50 mixture of (R)- and (S)-isomers. Racemic albuterol and the single isomer version (R)-albuterol (levalbuterol) were compared in a randomized, double-blind, dose-ranging five-way crossover study in patients (n = 20) with mild persistent to moderate persistent asthma. Placebo, racemic albuterol (2.50 mg), or levalbuterol (0.31, 0.63, or 1.25 mg) were delivered as single, nebulized doses to 5 male and 15 female ...
| Known for Racemic Albuterol | Patients Asthma | Bronchodilator Agents | Mild Persistent | Forced Expiratory |
